|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: C14orf119 |
Gene summary for C14ORF119 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | C14orf119 | Gene ID | 55017 |
| Gene name | chromosome 14 open reading frame 119 | |
| Gene Alias | C14orf119 | |
| Cytomap | 14q11.2 | |
| Gene Type | protein-coding | GO ID | GO:0005575 | UniProtAcc | Q9NWQ9 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 55017 | C14orf119 | LZE4T | Human | Esophagus | ESCC | 7.47e-22 | 6.53e-01 | 0.0811 |
| 55017 | C14orf119 | LZE5T | Human | Esophagus | ESCC | 4.72e-10 | 4.55e-01 | 0.0514 |
| 55017 | C14orf119 | LZE7T | Human | Esophagus | ESCC | 7.06e-09 | 3.38e-01 | 0.0667 |
| 55017 | C14orf119 | LZE8T | Human | Esophagus | ESCC | 2.12e-09 | 3.36e-01 | 0.067 |
| 55017 | C14orf119 | LZE20T | Human | Esophagus | ESCC | 2.56e-11 | 1.59e-01 | 0.0662 |
| 55017 | C14orf119 | LZE22D1 | Human | Esophagus | HGIN | 1.80e-03 | -7.77e-02 | 0.0595 |
| 55017 | C14orf119 | LZE22T | Human | Esophagus | ESCC | 3.32e-10 | 2.00e-01 | 0.068 |
| 55017 | C14orf119 | LZE24T | Human | Esophagus | ESCC | 1.53e-17 | 6.57e-01 | 0.0596 |
| 55017 | C14orf119 | LZE21T | Human | Esophagus | ESCC | 3.05e-08 | 3.45e-01 | 0.0655 |
| 55017 | C14orf119 | LZE6T | Human | Esophagus | ESCC | 1.92e-08 | 7.87e-01 | 0.0845 |
| 55017 | C14orf119 | P1T-E | Human | Esophagus | ESCC | 4.85e-13 | 5.23e-01 | 0.0875 |
| 55017 | C14orf119 | P2T-E | Human | Esophagus | ESCC | 8.41e-25 | 5.36e-01 | 0.1177 |
| 55017 | C14orf119 | P4T-E | Human | Esophagus | ESCC | 6.65e-41 | 1.03e+00 | 0.1323 |
| 55017 | C14orf119 | P5T-E | Human | Esophagus | ESCC | 6.53e-43 | 8.71e-01 | 0.1327 |
| 55017 | C14orf119 | P8T-E | Human | Esophagus | ESCC | 1.33e-38 | 8.84e-01 | 0.0889 |
| 55017 | C14orf119 | P9T-E | Human | Esophagus | ESCC | 1.47e-29 | 8.22e-01 | 0.1131 |
| 55017 | C14orf119 | P10T-E | Human | Esophagus | ESCC | 9.83e-44 | 8.05e-01 | 0.116 |
| 55017 | C14orf119 | P11T-E | Human | Esophagus | ESCC | 4.84e-16 | 8.83e-01 | 0.1426 |
| 55017 | C14orf119 | P12T-E | Human | Esophagus | ESCC | 5.39e-60 | 1.26e+00 | 0.1122 |
| 55017 | C14orf119 | P15T-E | Human | Esophagus | ESCC | 8.20e-69 | 1.40e+00 | 0.1149 |
| Page: 1 2 3 4 5 6 7 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| C14orf119 | SNV | Missense_Mutation | c.44N>A | p.Ser15Tyr | p.S15Y | Q9NWQ9 | protein_coding | deleterious_low_confidence(0) | possibly_damaging(0.452) | TCGA-AR-A24H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | tamoxiphen | SD | |
| C14orf119 | SNV | Missense_Mutation | novel | c.114N>C | p.Glu38Asp | p.E38D | Q9NWQ9 | protein_coding | deleterious(0.01) | probably_damaging(0.996) | TCGA-D8-A4Z1-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | tamoxiphen | SD |
| C14orf119 | SNV | Missense_Mutation | novel | c.277G>A | p.Glu93Lys | p.E93K | Q9NWQ9 | protein_coding | tolerated(0.11) | possibly_damaging(0.572) | TCGA-DS-A1OB-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | carboplatin | PD |
| C14orf119 | SNV | Missense_Mutation | novel | c.184G>A | p.Val62Ile | p.V62I | Q9NWQ9 | protein_coding | tolerated(0.14) | benign(0.146) | TCGA-A5-A0G1-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| C14orf119 | SNV | Missense_Mutation | c.313N>T | p.Gly105Cys | p.G105C | Q9NWQ9 | protein_coding | deleterious(0.02) | probably_damaging(0.939) | TCGA-AP-A059-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| C14orf119 | SNV | Missense_Mutation | rs751433100 | c.161G>A | p.Arg54His | p.R54H | Q9NWQ9 | protein_coding | deleterious(0.01) | probably_damaging(0.988) | TCGA-AX-A1CE-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unspecific | Paclitaxel | SD |
| C14orf119 | SNV | Missense_Mutation | novel | c.26N>C | p.Met9Thr | p.M9T | Q9NWQ9 | protein_coding | tolerated_low_confidence(0.18) | benign(0) | TCGA-B5-A11Y-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| C14orf119 | SNV | Missense_Mutation | novel | c.251N>A | p.Gly84Glu | p.G84E | Q9NWQ9 | protein_coding | tolerated_low_confidence(0.08) | benign(0.013) | TCGA-B5-A1MX-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Hormone Therapy | megace | SD |
| C14orf119 | SNV | Missense_Mutation | rs751433100 | c.161N>A | p.Arg54His | p.R54H | Q9NWQ9 | protein_coding | deleterious(0.01) | probably_damaging(0.988) | TCGA-DF-A2KU-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | Unknown | I/II | Unknown | Unknown | SD |
| C14orf119 | SNV | Missense_Mutation | novel | c.322G>A | p.Glu108Lys | p.E108K | Q9NWQ9 | protein_coding | deleterious(0.01) | possibly_damaging(0.857) | TCGA-56-7221-01 | Lung | lung squamous cell carcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |